These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 34171684)
1. miR-155 and functional proteins of CD8+ T cells as potential prognostic biomarkers for relapsing-remitting multiple sclerosis. Elkhodiry AA; Zamzam DA; El Tayebi HM Mult Scler Relat Disord; 2021 Aug; 53():103078. PubMed ID: 34171684 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA‑155 modulation of CD8 Elkhodiry AA; Zamzam DA; El Tayebi HM Med Int (Lond); 2023; 3(2):20. PubMed ID: 37032715 [TBL] [Abstract][Full Text] [Related]
3. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis. Ahmadian-Elmi M; Bidmeshki Pour A; Naghavian R; Ghaedi K; Tanhaei S; Izadi T; Nasr-Esfahani MH Immunogenetics; 2016 Jan; 68(1):43-54. PubMed ID: 26563334 [TBL] [Abstract][Full Text] [Related]
4. Downregulation of miR-125a-5p and miR-218-5p in Peripheral Blood Mononuclear Cells of Patients with Relapsing-Remitting Multiple Sclerosis. Mosarrezaii Aghdam A; Rezaei S; Zarza Nalivan F; Babaie F; Amiri Nikpour MR; Torkamandi S Immunol Invest; 2022 Jul; 51(5):1149-1161. PubMed ID: 33866949 [TBL] [Abstract][Full Text] [Related]
5. Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients. Ghadiri N; Emamnia N; Ganjalikhani-Hakemi M; Ghaedi K; Etemadifar M; Salehi M; Shirzad H; Nasr-Esfahani MH Gene; 2018 Jun; 659():109-117. PubMed ID: 29551498 [TBL] [Abstract][Full Text] [Related]
6. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis. Honardoost MA; Kiani-Esfahani A; Ghaedi K; Etemadifar M; Salehi M Gene; 2014 Jul; 544(2):128-33. PubMed ID: 24792898 [TBL] [Abstract][Full Text] [Related]
7. Analysis of potential microRNA biomarkers for multiple sclerosis. Al-Temaimi R; Alshammari N; Alroughani R Exp Mol Pathol; 2024 Jun; 137():104903. PubMed ID: 38772208 [TBL] [Abstract][Full Text] [Related]
8. Characterization of antigen-specific CD8+ memory T cell subsets in peripheral blood of patients with multiple sclerosis. Liu PJ; Yang TT; Fan ZX; Yuan GB; Ma L; Wang ZY; Lu JF; Yuan BY; Zou WL; Zhang XH; Liu GZ Front Immunol; 2023; 14():1110672. PubMed ID: 37215118 [TBL] [Abstract][Full Text] [Related]
9. Circulating CD8+CD56-perforin+ T cells are increased in multiple sclerosis patients. Giovanni F; Domenico P; Alessandro M; Raffaele I; Viviana N; Katia PA; Paola BA J Neuroimmunol; 2011 Dec; 240-241():137-41. PubMed ID: 22001684 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta. Karimi L; Eskandari N; Shaygannejad V; Zare N; Andalib A; Khanahmad H; Mirmosayyeb O Iran J Allergy Asthma Immunol; 2020 Aug; 19(4):416-425. PubMed ID: 33463108 [TBL] [Abstract][Full Text] [Related]
14. Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients. Arisi I; Malimpensa L; Manzini V; Brandi R; Gosetti di Sturmeck T; D'Amelio C; Crisafulli S; Ferrazzano G; Belvisi D; Malerba F; Florio R; Pascale E; Soreq H; Salvetti M; Cattaneo A; D'Onofrio M; Conte A Front Immunol; 2023; 14():1234869. PubMed ID: 38152407 [TBL] [Abstract][Full Text] [Related]
15. miR-141 and miR-200a, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis. Naghavian R; Ghaedi K; Kiani-Esfahani A; Ganjalikhani-Hakemi M; Etemadifar M; Nasr-Esfahani MH PLoS One; 2015; 10(5):e0124555. PubMed ID: 25938517 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression. Mancuso R; Hernis A; Agostini S; Rovaris M; Caputo D; Clerici M J Transl Med; 2015 May; 13():148. PubMed ID: 25947625 [TBL] [Abstract][Full Text] [Related]
17. miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study. Sağır F; Ersoy Tunalı N; Tombul T; Koral G; Çırak S; Yılmaz V; Türkoğlu R; Tüzün E Genet Test Mol Biomarkers; 2021 Nov; 25(11):720-726. PubMed ID: 34788141 [No Abstract] [Full Text] [Related]
19. Altered Expression of miR-326 in T Cell-derived Exosomes of Patients with Relapsing-remitting Multiple Sclerosis. Azimi M; Ghabaee M; Naser Moghadasi A; Izad M Iran J Allergy Asthma Immunol; 2019 Feb; 18(1):108-113. PubMed ID: 30848579 [TBL] [Abstract][Full Text] [Related]
20. Increased expression of mir-301a in PBMCs of patients with relapsing-remitting multiple sclerosis is associated with reduced NKRF and PIAS3 expression levels and disease activity. Tavakolpour V; Shokri G; Naser Moghadasi A; Mozafari Nahavandi P; Hashemi M; Kouhkan F J Neuroimmunol; 2018 Dec; 325():79-86. PubMed ID: 30316680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]